Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2008

View Archived Issues

Targeting galectin-1 may be useful to prevent pregnancy loss

Studies support serotonin inverse agonist combination therapy for schizophrenia

New site-directed nanoparticle delivery system useful to treat ocular inflammation in vivo

Cognition-enhancing activity of novel inverse agonist of GABA-A alpha 5 subunit receptors

Modulation of LR11 protein levels by dietary DHA may be beneficial for AD prevention

AstraZeneca submits sNDAs for Seroquel XR tablets

Can-Fite collaborates with academic institutes to develop CF-102

Efexor XL indication in U.K. now includes moderate-severe generalized SAD/social phobia

Innocoll doses first patient in phase III gentamicin surgical implant trial

NeoPharm files IND for novel docetaxel liposomal delivery system

Pfizer completes tender offer relating to outstanding shares of Coley Pharmaceutical

Recent Jerini patent discloses novel agents for ocular disorders

Pfizer launches Ecalta for invasive candidiasis in non-neutropenic patients

Positive results reported for Zybrestat in platinum-resistant ovarian cancer

Prana Biotechnology completes phase IIa trial of PBT-2 in Alzheimer's disease

Recent patents impart novel analgesic agents

FDA approves Sciele Pharma's new Sular formulation

FDA assigns priority review status to Schering-Plough's NDA for sugammadex

New HIV aspartyl protease inhibitors disclosed in recent Tibotec patent

Recent patents describe new antidiabetic agents

Sepracor and Bial collaborate on antiepileptic compound in U.S. and Canada

Positive preclinical ocular penetration data reported for topical Zybrestat in ophthalmology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...